Alzheimer Disease Blood-Based Biomarkers: Translation from Research into Clinical Use

Lance A Ladic,Mari L DeMarco,Nicholas J Ashton,Andrew J Saykin,Louis B Jacques

DOI: https://doi.org/10.1093/clinchem/hvae144

IF: 12.114

2024-11-10

Clinical Chemistry

Abstract:Recent FDA approvals of new disease-modifying therapies for Alzheimer disease (AD) has increased the clinical demand for tests of amyloid pathology that can be scaled for wider use. Concurrent advances in blood-based biomarker (BBB) assays have made it possible to perform minimally invasive and highly accessible laboratory testing for core biomarkers of this disease. While there are currently no FDA-approved blood tests for AD, many of the major in vitro diagnostic (IVD) companies have products in development (including several with breakthrough device status), and thus new IVD products are anticipated in the not-too-distant future. Existing diagnostic approaches, such as cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) imaging, are effective but are invasive and often more expensive (especially the latter) compared to blood tests. Additionally, these tests may not be widely accessible based on socioeconomic and geographic factors, as well as regulatory and reimbursement status. PET in particular requires administration of a radiolabeled tracer prior to imaging, necessitating proximity to a tracer production site or a well-validated supply chain, which often limits this technology to tertiary care centers in predominantly major urban centers. The future availability of plasma assays is poised to fundamentally change the diagnostic process for AD, as it may lower some of the barriers to testing faced by CSF and PET testing.

medical laboratory technology